Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Livzon Mabpharm study demonstrates its LZM008 (tocilizumab) is ‘similar’ to Genentech’s ACTEMRA® in male Chinese patients

Apr 4, 2023

A study published in Frontiers in Pharmacology has found that the pharmacokinetic characteristics and immunogenicity of Livzon Mabpharm’s LZM008 were similar to Genentech’s ACTEMRA®.  The safety profiles of LZM008 were similar in two groups with mild–moderate adverse effects.  The study was a randomised, double-blinded, single-dose, parallel-group phase I clinical trial conducted in Huashan Hospital and Wuxi People’s Hospital in China.  The incidence of treatment emergent adverse events was comparable in LZM008 and ACTEMRA® groups (98% versus 100%).  The study was funded by the Livzon Mabpharm Inc. and the Ministry of Science and Technology of China.

In February 2023, Fresenius Kabi demonstrated bioequivalence for its tocilizumab biosimilar.